Insider Buying: OncoCyte Co. (NASDAQ:OCX) CFO Purchases 20,000 Shares of Stock

OncoCyte Co. (NASDAQ:OCX) CFO Andrea S. James bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The stock was acquired at an average cost of $2.29 per share, with a total value of $45,800.00. Following the transaction, the chief financial officer now owns 53,670 shares of the company’s stock, valued at $122,904.30. This represents a 59.40 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

OncoCyte Stock Performance

Shares of OCX opened at $2.46 on Tuesday. The company’s fifty day simple moving average is $2.85 and its 200 day simple moving average is $2.95. OncoCyte Co. has a 1-year low of $1.98 and a 1-year high of $3.82.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The firm had revenue of $0.12 million during the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. During the same period in the previous year, the business posted ($0.57) earnings per share. Equities analysts forecast that OncoCyte Co. will post -2.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OncoCyte

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC grew its holdings in OncoCyte Co. (NASDAQ:OCX) by 12.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 103,980 shares of the company’s stock after buying an additional 11,289 shares during the period. Geode Capital Management LLC owned 0.62% of OncoCyte worth $296,000 at the end of the most recent quarter. 55.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

OCX has been the subject of a number of recent research reports. StockNews.com initiated coverage on shares of OncoCyte in a research note on Sunday. They set a “sell” rating for the company. Needham & Company LLC reiterated a “buy” rating and set a $4.25 target price on shares of OncoCyte in a report on Wednesday, November 13th.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.